176 related articles for article (PubMed ID: 6230629)
1. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
Chantraine A; Jung A; van Ouwenaller C; Donath A
Presse Med; 1984 Feb; 13(8):479-82. PubMed ID: 6230629
[TBL] [Abstract][Full Text] [Related]
2. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
[TBL] [Abstract][Full Text] [Related]
3. Treatment of malignant hypercalcaemia with clodronate.
Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
[TBL] [Abstract][Full Text] [Related]
5. Clodronate for osteolytic metastases due to breast cancer.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
[TBL] [Abstract][Full Text] [Related]
6. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
[TBL] [Abstract][Full Text] [Related]
8. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
9. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; van Ouwenaller C; Chantraine A; Donath A; Rosini S
N Engl J Med; 1981 Aug; 305(6):343-4. PubMed ID: 6454076
[No Abstract] [Full Text] [Related]
10. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Siris ES; Hyman GA; Canfield RE
Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
[TBL] [Abstract][Full Text] [Related]
11. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
Adami S; Salvagno G; Guarrera G; Bianchi G; Dorizzi R; Rosini S; Mobilio G; Lo Cascio V
J Urol; 1985 Dec; 134(6):1152-4. PubMed ID: 2932559
[TBL] [Abstract][Full Text] [Related]
12. [Diphosphonates in the treatment of bone metastases].
Jung A; Fleisch H
Schweiz Med Wochenschr; 1981 Dec; 111(49):1878-82. PubMed ID: 6460313
[TBL] [Abstract][Full Text] [Related]
13. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Major PP; Lipton A; Berenson J; Hortobagyi G
Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
[TBL] [Abstract][Full Text] [Related]
14. Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells.
Pollard M; Luckert PH
J Natl Cancer Inst; 1985 Nov; 75(5):949-54. PubMed ID: 2932588
[TBL] [Abstract][Full Text] [Related]
15. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.
Siris ES; Sherman WH; Baquiran DC; Schlatterer JP; Osserman EF; Canfield RE
N Engl J Med; 1980 Feb; 302(6):310-5. PubMed ID: 6444241
[TBL] [Abstract][Full Text] [Related]
16. The use of clodronate in multiple myeloma.
Delmas PD
Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
O'Rourke N; McCloskey E; Houghton F; Huss H; Kanis JA
J Clin Oncol; 1995 Apr; 13(4):929-34. PubMed ID: 7707121
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
[TBL] [Abstract][Full Text] [Related]
19. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
[TBL] [Abstract][Full Text] [Related]
20. Drug treatment of primary hyperparathyroidism: use of clodronate disodium.
Douglas DL; Kanis JA; Paterson AD; Beard DJ; Cameron EC; Watson ME; Woodhead S; Williams J; Russell RG
Br Med J (Clin Res Ed); 1983 Feb; 286(6365):587-90. PubMed ID: 6218861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
